NEVIRAPINE TEVA LP 400 mg, extended-release tablet 30 tablets
Active ingredients: Nevirapine
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Extended-release tablet30 tabletsorale
Marketing discontinued
Package details
Original BDPM fields are shown in French.
- Official name
- NEVIRAPINE TEVA LP 400 mg, comprimé à libération prolongée
- Pharmaceutical form
- comprimé à libération prolongée
- Route of administration
- orale
- Presentation description
- 30 plaquette(s) OPA : polyamide orienté aluminium PVC de 1 comprimé(s)
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 31 Oct 2017
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66890524CIP73010210CIP133400930102107Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| NÉVIRAPINE ANHYDREcomprimé | 400 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.